Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18206
Country/Region: Kenya
Year: 2016
Main Partner: Kenya Conference of Catholic Bishops
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: HHS/CDC
Total Funding: $11,006,593 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,317,292
Care: TB/HIV (HVTB) $729,595
Care: Pediatric Care and Support (PDCS) $432,697
Testing: HIV Testing and Counseling (HVCT) $306,237
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,117,615
Treatment: Adult Treatment (HTXS) $5,454,112
Treatment: Pediatric Treatment (PDTX) $649,045
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 6,525
HTS_TST Age/sex: 1-9 2017 49,672
HTS_TST Age/sex: 10-14 Female 2017 9,175
HTS_TST Age/sex: 10-14 Male 2017 7,728
HTS_TST Age/sex: 15-19 Female 2017 19,237
HTS_TST Age/sex: 15-19 Male 2017 15,786
HTS_TST Age/sex: 20-24 Female 2017 36,428
HTS_TST Age/sex: 20-24 Male 2017 23,926
HTS_TST Age/sex: 25-49 Female 2017 104,789
HTS_TST Age/sex: 25-49 Male 2017 52,519
HTS_TST Age/sex: 50+ Female 2017 21,718
HTS_TST Age/sex: 50+ Male 2017 16,050
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 45,678
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 32,676
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 219,277
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 112,109
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 409,773
HTS_TST Service Delivery Point (Facility): Index testing 2017 5,752
HTS_TST Service Delivery Point (Facility): Inpatient 2017 23,714
HTS_TST Service Delivery Point (Facility): Other PITC 2017 3,133
HTS_TST Service Delivery Point (Facility): Outpatient 2017 244,136
HTS_TST Service Delivery Point (Facility): Pediatric 2017 4,108
HTS_TST Service Delivery Point (Facility): PMTCT 2017 23,705
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 883
HTS_TST Service Delivery Point (Facility): VCT 2017 101,855
HTS_TST Service Delivery Point (Facility): VMMC 2017 2,456
HTS_TST Sum of Age/Sex disaggregates 2017 307,356
HTS_TST Sum of Aggregated Age/Sex <15 2017 78,354
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 331,386
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 409,740
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 139
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 86
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 233
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 185
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 754
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 453
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 2,928
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 1,849
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 372
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 257
HTS_TST_POS Test Result by Age: Positive: <1 2017 209
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 700
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,248
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 735
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 8,223
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 4,979
PMTCT_ART Already on ART at beginning of current pregnancy 2017 4,239
PMTCT_ART New on ART 2017 1,486
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 50,476
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 4,066
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 2,339
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 144
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 140
PMTCT_EID Sum of Infant Age disaggregates 2017 6,405
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 87
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 455
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 2,926
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 6,652
PMTCT_STAT By: Known positives at entry 2017 3,524
PMTCT_STAT By: Number of new positives identified 2017 1,284
PMTCT_STAT Number of new ANC and L&D clients 2017 50,476
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 50,476
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 3
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 29
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 221
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 1,277
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 258
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 7
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 80
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 448
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 90
PMTCT_STAT Sum of Positives Status disaggregates 2017 4,808
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 87
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 455
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 2,926
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 6,246
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 82
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,184
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 120
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,407
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,793
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,793
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 22,638
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 1
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 22,460
TB_SCREENDX Screen Result: Screened Positive for TB 2017 25,125
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 77,750
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 35,858
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 5,714
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,550
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 125,752
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 228
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,398
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 285
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,824
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 5,735
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 5,735
TX_CURR Age/Sex: <1 2017 112
TX_CURR Age/Sex: <1-9 2017 7,098
TX_CURR Age/Sex: 10-14 Female 2017 2,085
TX_CURR Age/Sex: 10-14 Male 2017 2,092
TX_CURR Age/Sex: 15-19 Female 2017 2,001
TX_CURR Age/Sex: 15-19 Male 2017 1,450
TX_CURR Age/Sex: 20-24 Female 2017 6,863
TX_CURR Age/Sex: 20-24 Male 2017 1,732
TX_CURR Age/Sex: 25-49 Female 2017 57,967
TX_CURR Age/Sex: 25-49 Male 2017 24,592
TX_CURR Age/Sex: 50+ Female 2017 11,443
TX_CURR Age/Sex: 50+ Male 2017 8,317
TX_CURR Aggregated Age/Sex: <15 Female 2017 5,776
TX_CURR Aggregated Age/Sex: <15 Male 2017 5,611
TX_CURR Aggregated Age/Sex: 15+ Female 2017 78,274
TX_CURR Aggregated Age/Sex: 15+ Male 2017 36,091
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 125,752
TX_CURR Sum of age/sex disaggregates 2017 3,451
TX_CURR Sum of Aggregated Age/Sex <15 2017 11,387
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 114,365
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 125,752
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 1,546
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 1,355
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 16,111
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 8,290
TX_NEW By Age/Sex: <1 2017 235
TX_NEW By Age/Sex: 1-9 2017 1,747
TX_NEW By Age/Sex: 10-14 Female 2017 410
TX_NEW By Age/Sex: 10-14 Male 2017 290
TX_NEW By Age/Sex: 15-19 Female 2017 682
TX_NEW By Age/Sex: 15-19 Male 2017 207
TX_NEW By Age/Sex: 20-24 Female 2017 2,139
TX_NEW By Age/Sex: 20-24 Male 2017 427
TX_NEW By Age/Sex: 25-49 Female 2017 10,284
TX_NEW By Age/Sex: 25-49 Male 2017 5,616
TX_NEW By Age/Sex: 50+ Female 2017 1,801
TX_NEW By Age/Sex: 50+ Male 2017 1,477
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 25,315
TX_NEW Sum of Age/Sex disaggregates 2017 23,333
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 27,302
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 116,838
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 113,242
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 5,217
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 5,075
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 70,458
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 32,492
TX_PVLS Numerator: Indication: Routine 2017 112,665
TX_PVLS Numerator: Indication: Targeted 2017 612
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5,217
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5,075
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 70,458
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 32,492
TX_PVLS_den Denominator: Indication: Routine 2017 106,368
TX_PVLS_den Denominator: Indication: Targeted 2017 4,392
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 223
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,605
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 374
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 272
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 627
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 196
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,942
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 390
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 9,236
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,074
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,623
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,345
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,295
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,084
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 13,156
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,876
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 22,903
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 25,313
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 235
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,747
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 410
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 290
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 682
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 207
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,139
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 427
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 10,284
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,638
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,801
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,477
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,429
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,253
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 14,906
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,727
Cross Cutting Budget Categories and Known Amounts Total: $907,946
Gender: Gender Based Violence (GBV) $453,973
GBV Prevention
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $453,973
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research